These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

589 related items for PubMed ID: 16567708

  • 1. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses.
    O'Connor PW, Li D, Freedman MS, Bar-Or A, Rice GP, Confavreux C, Paty DW, Stewart JA, Scheyer R, Teriflunomide Multiple Sclerosis Trial Group, University of British Columbia MS/MRI Research Group.
    Neurology; 2006 Mar 28; 66(6):894-900. PubMed ID: 16567708
    [Abstract] [Full Text] [Related]

  • 2. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group.
    Comi G, Filippi M, Wolinsky JS.
    Ann Neurol; 2001 Mar 28; 49(3):290-7. PubMed ID: 11261502
    [Abstract] [Full Text] [Related]

  • 3. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ.
    Clin Ther; 2006 Apr 28; 28(4):461-74. PubMed ID: 16750460
    [Abstract] [Full Text] [Related]

  • 4. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Confavreux C, O'Connor P, Comi G, Freedman MS, Miller AE, Olsson TP, Wolinsky JS, Bagulho T, Delhay JL, Dukovic D, Truffinet P, Kappos L, TOWER Trial Group.
    Lancet Neurol; 2014 Mar 28; 13(3):247-56. PubMed ID: 24461574
    [Abstract] [Full Text] [Related]

  • 5. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
    Hurwitz BJ, Jeffery D, Arnason B, Bigley K, Coyle P, Goodin D, Kaba S, Kirzinger S, Lynch S, Mandler R, Mikol D, Rammohan K, Sater R, Sriram S, Thrower B, Boateng F, Jakobs P, Wash MB, Bogumil T.
    Clin Ther; 2008 Jun 28; 30(6):1102-12. PubMed ID: 18640466
    [Abstract] [Full Text] [Related]

  • 6. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS.
    Polman C, Barkhof F, Sandberg-Wollheim M, Linde A, Nordle O, Nederman T, Laquinimod in Relapsing MS Study Group.
    Neurology; 2005 Mar 22; 64(6):987-91. PubMed ID: 15781813
    [Abstract] [Full Text] [Related]

  • 7. Randomized trial of oral teriflunomide for relapsing multiple sclerosis.
    O'Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, Olsson TP, Benzerdjeb H, Truffinet P, Wang L, Miller A, Freedman MS, TEMSO Trial Group.
    N Engl J Med; 2011 Oct 06; 365(14):1293-303. PubMed ID: 21991951
    [Abstract] [Full Text] [Related]

  • 8. Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis.
    Birnbaum G, Cree B, Altafullah I, Zinser M, Reder AT.
    Neurology; 2008 Oct 28; 71(18):1390-5. PubMed ID: 18525027
    [Abstract] [Full Text] [Related]

  • 9. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial.
    Fazekas F, Lublin FD, Li D, Freedman MS, Hartung HP, Rieckmann P, Sørensen PS, Maas-Enriquez M, Sommerauer B, Hanna K, PRIVIG Study Group, UBC MS/MRI Research Group.
    Neurology; 2008 Jul 22; 71(4):265-71. PubMed ID: 18645164
    [Abstract] [Full Text] [Related]

  • 10. Interferon beta-1b is effective in Japanese RRMS patients: a randomized, multicenter study.
    Saida T, Tashiro K, Itoyama Y, Sato T, Ohashi Y, Zhao Z, Interferon Beta-1b Multiple Sclerosis Study Group of Japan.
    Neurology; 2005 Feb 22; 64(4):621-30. PubMed ID: 15728282
    [Abstract] [Full Text] [Related]

  • 11. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
    Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P, FREEDOMS Study Group.
    N Engl J Med; 2010 Feb 04; 362(5):387-401. PubMed ID: 20089952
    [Abstract] [Full Text] [Related]

  • 12. Glatiramer acetate in combination with minocycline in patients with relapsing--remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial.
    Metz LM, Li D, Traboulsee A, Myles ML, Duquette P, Godin J, Constantin M, Yong VW, GA/minocycline study investigators.
    Mult Scler; 2009 Oct 04; 15(10):1183-94. PubMed ID: 19776092
    [Abstract] [Full Text] [Related]

  • 13. Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial.
    Chitnis T, Banwell B, Kappos L, Arnold DL, Gücüyener K, Deiva K, Skripchenko N, Cui LY, Saubadu S, Hu W, Benamor M, Le-Halpere A, Truffinet P, Tardieu M, TERIKIDS Investigators.
    Lancet Neurol; 2021 Dec 04; 20(12):1001-1011. PubMed ID: 34800398
    [Abstract] [Full Text] [Related]

  • 14. A double blind, placebo-controlled, phase II, add-on study of cyclophosphamide (CTX) for 24 months in patients affected by multiple sclerosis on a background therapy with interferon-beta study denomination: CYCLIN.
    Patti F, Amato MP, Filippi M, Gallo P, Trojano M, Comi GC.
    J Neurol Sci; 2004 Aug 15; 223(1):69-71. PubMed ID: 15261564
    [Abstract] [Full Text] [Related]

  • 15. Teriflunomide added to interferon-β in relapsing multiple sclerosis: a randomized phase II trial.
    Freedman MS, Wolinsky JS, Wamil B, Confavreux C, Comi G, Kappos L, Olsson TP, Miller A, Benzerdjeb H, Li H, Simonson C, O'Connor PW, Teriflunomide Multiple Sclerosis Trial Group and the MRI Analysis Center.
    Neurology; 2012 Jun 05; 78(23):1877-85. PubMed ID: 22622860
    [Abstract] [Full Text] [Related]

  • 16. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group.
    Neurology; 1999 Aug 11; 53(3):457-65. PubMed ID: 10449104
    [Abstract] [Full Text] [Related]

  • 17. Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial.
    Bar-Or A, Vollmer T, Antel J, Arnold DL, Bodner CA, Campagnolo D, Gianettoni J, Jalili F, Kachuck N, Lapierre Y, Niino M, Oger J, Price M, Rhodes S, Robinson WH, Shi FD, Utz PJ, Valone F, Weiner L, Steinman L, Garren H.
    Arch Neurol; 2007 Oct 11; 64(10):1407-15. PubMed ID: 17698695
    [Abstract] [Full Text] [Related]

  • 18. Teriflunomide for multiple sclerosis.
    He D, Xu Z, Dong S, Zhang H, Zhou H, Wang L, Zhang S.
    Cochrane Database Syst Rev; 2012 Dec 12; 12():CD009882. PubMed ID: 23235682
    [Abstract] [Full Text] [Related]

  • 19. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients.
    Río J, Rovira A, Tintoré M, Huerga E, Nos C, Tellez N, Tur C, Comabella M, Montalban X.
    Mult Scler; 2008 May 12; 14(4):479-84. PubMed ID: 18562504
    [Abstract] [Full Text] [Related]

  • 20. Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS.
    Cohen JA, Rovaris M, Goodman AD, Ladkani D, Wynn D, Filippi M, 9006 Study Group.
    Neurology; 2007 Mar 20; 68(12):939-44. PubMed ID: 17372130
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.